The evidence for skin.
The copper peptide and the blend it sits in: the skin studies, the gene work, and what has never been tested.
Studies on this page
15 fetched
each read from its source
A skin protocol here is the blend, and the compound in it that matters for skin is GHK-Cu, the copper tripeptide. This page sets out what has been studied for it and for the three peptides beside it in the vial.
The copper tripeptide has decades of laboratory work and one fetched randomised skin trial, which was negative. Both of those facts belong on the same page.
GHK-Cu
GHK is a three-amino-acid sequence that binds copper, present in human plasma and falling with age. It is the oldest and most-studied compound in the blend, with decades of laboratory work on collagen, elastin and gene expression behind it.
It is also the compound where the gap between mechanism and outcome is easiest to see, because the mechanism papers are strong and the one fetched randomised skin trial was negative.
What has been studied.
| Study | Who | n | How long |
|---|---|---|---|
| Bioimpacts 20251review, 2025 | The topical literature | n/a | n/a |
| A 2025 review of the peptide as a topical anti-wrinkle ingredient, which concludes that published information on skin permeability and effectiveness is insufficient. | |||
| Int J Mol Sci 20182review | The published literature on the copper tripeptide | n/a | n/a |
| A review from the group that originated the peptide, which is worth knowing when reading it. It sets out collagen and elastin synthesis, fibroblast support and gene expression work. | |||
| Genome Med 20123human tissue and computational | Lung tissue from smokers with emphysema, 64 samples from 8 lungs | 64 samples | n/a |
| A gene expression signature of lung destruction was reversed in fibroblasts by the tripeptide. This is the strongest mechanism paper and it is not a clinical outcome. | |||
| Arch Facial Plast Surg 20064RCT, topical | Patients after carbon dioxide laser skin resurfacing | 13 | 12 weeks |
| The fetched randomised skin trial, and it was negative: computer analysis and blinded evaluators found no significant difference between the groups. | |||
What it is approved for.
- None found as a medicine on any page fetched for this build. It is widely used as a cosmetic ingredient, which is a different regulatory category and not an approval. Source.
What has not been studied.
- No randomised trial of injected GHK-Cu for skin, in any population, was found. The fetched randomised trial applied it to the skin after laser resurfacing and found no significant difference.
- A 2025 review concludes that published information on skin permeability and effectiveness is insufficient, which is a review of the topical form, the one with the most data.
- Nothing on wrinkle outcomes over a year, nothing in Filipino skin, nothing on the injected form at all.
Side effects, and who stopped.
No safety signal appears in the fetched records, and no adequate human safety study of the injected form exists to produce one. Absence of reported harm from studies that were not done is not a safety finding.
WHAT THIS MEANS FOR YOU
The biology is real and well described; the clinical proof for skin is not there in the fetched record, and the one randomised skin trial was negative. If your skin changes on a protocol that contains it, that is worth noting in your own log, and it is not something the published literature would have predicted.
BPC-157
BPC-157 is a fifteen-amino-acid fragment of a protein found in gastric juice. It is the compound most associated with tendon, ligament and gut repair, and it is one of the four peptides in the blend that most protocols here add at week five.
It is also the clearest example of the gap this wing exists to show. The mechanism work is genuinely interesting and almost all of it is in animals and cells.
What has been studied.
| Study | Who | n | How long |
|---|---|---|---|
| Curr Rev Musculoskelet Med 20255narrative review, 2025 | The published literature, preclinical and clinical | n/a | n/a |
| An independent review of the whole literature. It describes regenerative effects across animal models and sets them against the regulatory position and the absence of human trials. | |||
| HSS J 20256systematic review, 2025 | The orthopaedic sports medicine literature to June 2024 | n/a | n/a |
| A systematic review from a sports medicine perspective. It states plainly that the compound lacks approval and is banned in professional sport while being increasingly used. | |||
| Altern Ther Health Med 20257pilot, human, intravenous | Two patients at a private clinic | 2 | 3 days |
| The smallest possible human study, and the only fetched one of intravenous use. Two people, blood work before and after, no efficacy endpoint. | |||
| J Appl Physiol (1985) 20118preclinical | Rat Achilles tendon tissue and cultured tendon cells | n/a | n/a |
| Tendon cell outgrowth and migration increased, and cell survival under oxidative stress improved. This is cell and animal work, not a human result. | |||
What it is approved for.
- None. A 2025 systematic review states plainly that it lacks United States Food and Drug Administration approval and that its use is banned in professional sport, while being increasingly used by clinicians and athletes. Source.
What has not been studied.
- There is no published randomised controlled trial of injected BPC-157 for a musculoskeletal injury in humans. The two 2025 reviews fetched here were written precisely because the compound is widely used and that trial does not exist.
- The only fetched human study of intravenous use had two participants and no efficacy endpoint at all.
- Long-term human safety data does not exist, in any population, at any duration.
Side effects, and who stopped.
There is not enough human data to describe a side-effect profile, which is itself the finding. The 2025 narrative review sets out to assess safety concerns and works from preclinical material because that is what there is.
WHAT THIS MEANS FOR YOU
The mechanism is plausible and the animal work is consistent, and that is a different thing from knowing it works in you. If you use it, use it knowing that you are ahead of the evidence rather than behind it, and that the reviews written by people who study this for a living say the same.
TB-500
TB-500 is sold as a fragment related to thymosin beta-4, a 43-amino-acid protein involved in cell migration and wound repair. The distinction between the fragment and the full-length protein is not a technicality here: it is the single most important thing on this page.
The human trials that exist, and several do, used full-length thymosin beta-4, applied to skin, to the eye, or given intravenously in a hospital. A laboratory analysis of the product sold as TB-500 identified a seven-amino-acid acetylated fragment instead.
What has been studied.
| Study | Who | n | How long |
|---|---|---|---|
| Cardiovasc Res 20259preclinical and clinical, 2025 | Mice, and people after a heart attack treated with stenting | Both | 28 days in mice |
| Recombinant full-length thymosin beta-4 improved cardiac function in mice and was carried into a group of patients after reperfusion. | |||
| Cornea 201510phase 2 RCT, eye drops | Patients with severe dry eye disease | 9 | 28 days with a 28-day follow-up |
| Signs and symptoms improved against vehicle control. Again the full-length peptide, and applied to the eye. | |||
| Drug Test Anal 201211laboratory analysis | The product sold as TB-500 | n/a | n/a |
| The paper that matters most for anyone buying this. Analysis of the product identified an acetylated seven-amino-acid fragment of thymosin beta-4, not the full-length peptide that the human trials used. | |||
| Ann N Y Acad Sci 201012phase 2 RCT, topical | Patients with venous stasis ulcers at eight European sites | 73 | Dose-escalation study |
| Full-length thymosin beta-4 applied to the skin. The safety profile at all doses was deemed acceptable. Note that this is the full-length peptide, not the fragment sold as TB-500. | |||
| Ann N Y Acad Sci 201013phase 1 RCT, intravenous | Healthy volunteers, four dose cohorts | 40 | Single dose then 14 daily doses |
| The human safety study of the full-length peptide given intravenously. Adverse events were infrequent and mild or moderate, with no dose-limiting toxicity. | |||
What it is approved for.
- None found on any page fetched for this build, for either the fragment or the full-length peptide. Source.
What has not been studied.
- Nobody has published a human trial of the seven-amino-acid fragment that the analysis found in the product. Every human trial fetched here used the full-length peptide.
- Nobody has published a human trial of either form injected under the skin for a musculoskeletal injury, which is how it is used.
- The dermal and ophthalmic trials were in wounds and dry eye, not in tendons.
Side effects, and who stopped.
The phase 1 intravenous trial of the full-length peptide in forty healthy volunteers reported adverse events that were infrequent and mild or moderate, with no dose-limiting toxicity and no serious adverse events. That is real safety data, and it is about a molecule that may not be the one in the vial.
WHAT THIS MEANS FOR YOU
Read the trial column on this page and then read the compound column, because they are not always the same molecule. What is known is that the full-length protein was tolerated intravenously in healthy volunteers and helped skin and eye conditions in small trials. What is not known is what the fragment does.
KPV
KPV is the last three amino acids of alpha-melanocyte-stimulating hormone, included in the blend for its anti-inflammatory action. It is the smallest and least-studied of the four.
What has been studied.
| Study | Who | n | How long |
|---|---|---|---|
| Gastroenterology 200814preclinical | Human intestinal cell lines, human T cells, and two mouse colitis models | n/a | n/a |
| The tripeptide reduced intestinal inflammation through a peptide transporter in cells and in mice. No human trial was found. | |||
| Inflamm Bowel Dis 200815preclinical | Two mouse models of inflammatory bowel disease | n/a | n/a |
| Anti-inflammatory activity in both models, including in mice with a non-functional melanocortin receptor. | |||
What it is approved for.
- None found on any page fetched for this build.
What has not been studied.
- No human trial of any kind was found. Both fetched papers are cell and mouse work in models of inflammatory bowel disease.
- Nothing on skin, nothing on tendon, nothing on the uses it appears in a blend for.
Side effects, and who stopped.
No human safety data was found, because no human study was found.
WHAT THIS MEANS FOR YOU
This is the compound on the shape and recovery protocols with the least evidence behind it, and it is a small part of a blend rather than something anyone takes alone. Knowing that is the point of this page. Take it to a doctor who knows you before you begin.
Three minutes. Built from your answers.
Get startedMechanism is not a result.
The gene expression work on the copper tripeptide is unusually good. A signature of lung tissue destruction was reversed by it in fibroblasts, collagen and elastin synthesis rise in cell work, and the peptide is present in human plasma and falls with age. Any of that would justify running a trial.
The trial that was run, on skin after laser resurfacing, found no significant difference between the groups on computer analysis or from blinded evaluators. A 2025 review of the topical form concludes that published information on effectiveness is insufficient. That is where the evidence for skin actually stands, and it is not where the marketing for this ingredient stands.
What to measure instead.
Since the literature will not tell you, photograph your own face in the same light on day one and at day 90. That single habit is worth more to you than any claim on any label, because it measures the only person whose result you care about.
The skin protocol also runs alongside things that have far better evidence than any peptide: sleep, sun exposure managed sensibly, and not smoking. The foundations wing covers those and they are free. Take it to a doctor who knows you before you begin.
Questions
Does the copper peptide actually work on skin?
The mechanism work is strong and the one fetched randomised skin trial was negative. A 2025 review of the topical form says the published information on effectiveness is insufficient. Anyone claiming it is proven for wrinkles is going beyond the fetched record.
Is the injected form better than a cream?
No fetched trial compares them, and there is no randomised trial of the injected form for skin at all. The trial that exists, and the reviews, are about topical use.
What has the best skin evidence on this site?
Nothing on this site has strong randomised skin evidence, and this page says so rather than picking a winner. Sleep and sun behaviour have better evidence than any compound here.
Why is the blend used for skin then?
Because the copper tripeptide is in it, and the mechanism work is real. It joins at week five as support, never as the core, and this page is why.
Sources
Every record below was fetched on the date shown. Nothing on this page is cited that did not fetch.
- 01Mortazavi SM, et al. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts 2025. PubMed 39963574 · doi · read 2026-09-07
- 02Pickart L, et al. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018. PubMed 29986520 · doi · read 2026-09-07
- 03Campbell JD, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med 2012. PubMed 22937864 · doi · read 2026-09-07
- 04Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006. PubMed 16847171 · doi · read 2026-09-07
- 05McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025. PubMed 40789979 · doi · read 2026-09-07
- 06Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PubMed 40756949 · doi · read 2026-09-07
- 07Lee E, et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PubMed 40131143 · read 2026-09-07
- 08Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) 2011. PubMed 21030672 · doi · read 2026-09-07
- 09Zhang Y, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res 2025. PubMed 41229390 · doi · read 2026-09-07
- 10Sosne G, et al. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea 2015. PubMed 25826322 · doi · read 2026-09-07
- 11Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012. PubMed 22962027 · doi · read 2026-09-07
- 12Guarnera G, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci 2010. PubMed 20536470 · doi · read 2026-09-07
- 13Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010. PubMed 20536472 · doi · read 2026-09-07
- 14Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008. PubMed 18061177 · doi · read 2026-09-07
- 15Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008. PubMed 18092346 · doi · read 2026-09-07
Your 90-day protocol, made for you. Delivered.
Get startedRelated
Longevity Manila builds your protocol from your answers. Fulfilment is by Primara Labs, our partner and supplier. Take it to a doctor who knows you before you begin.